Activities on new projects have been started in the company:
Our company has won a tender on providing full service for a clinical study of immunotherapy for an orphan genetic immune system disorder, for an international company. The study will be conducted at 5 sites in Russia; it is planned to enroll 20 patients.
Our company has received a request from one of the leading companies for the conduct of a bioequivalence study of Dapoxetine.
Smooth has been awarded with a project to conduct a phase III study of a combination drug for the treatment of pain syndrome, for an international company. It is planned to include 190 female patients at 8 sites in Russia.
Our team have been launching a new patient support programme. There will be 3,800 patients with multiple sclerosis participating in the programme.
Our specialists have visited the seminar on Safety monitoring of medicinal products organized by the Federal Service for Surveillance in Healthcare (RosZdravNadzor).
HDV patient enrollment into the ongoing phase II study in Russia has been completed. The enrollment in Germany is in active stage.
Close-out visits have been conducted in the phase III study of a product for treatment of pain under trauma.
Two bioequivalence studies of Pregabalin have been launched.
Database closure has been performed in the phase III study for treatment of ischemic stroke.
Initiation visits for the study of a product for treatment of metabolic liver damage have been conducted. First patients will be enrolled in the end of August.
Our Quality assurance and trainings department will conduct two trainings in August:
-Presentation skills-Refreshment training on monitoring of a clinical trial